Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies

Publications

Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study.

Journal article

Sallman DA. et al, (2023), J Clin Oncol

Author Correction: A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns (Nature Communications, (2020), 11, 1, (728), 10.1038/s41467-019-13825-8)

Journal article

Jiao W. et al, (2022), Nature Communications, 13

Author Correction: Combined burden and functional impact tests for cancer driver discovery using DriverPower (Nature Communications, (2020), 11, 1, (734), 10.1038/s41467-019-13929-1)

Journal article

Shuai S. et al, (2022), Nature Communications, 13

Author Correction: Divergent mutational processes distinguish hypoxic and normoxic tumours (Nature Communications, (2020), 11, 1, (737), 10.1038/s41467-019-14052-x)

Journal article

Bhandari V. et al, (2022), Nature Communications, 13

Author Correction: Genomic footprints of activated telomere maintenance mechanisms in cancer (Nature Communications, (2020), 11, 1, (733), 10.1038/s41467-019-13824-9)

Journal article

Sieverling L. et al, (2022), Nature Communications, 13

Author Correction: High-coverage whole-genome analysis of 1220 cancers reveals hundreds of genes deregulated by rearrangement-mediated cis-regulatory alterations (Nature Communications, (2020), 11, 1, (736), 10.1038/s41467-019-13885-w)

Journal article

Zhang Y. et al, (2022), Nature Communications, 13

Author Correction: Inferring structural variant cancer cell fraction (Nature Communications, (2020), 11, 1, (730), 10.1038/s41467-020-14351-8)

Journal article

Cmero M. et al, (2022), Nature Communications, 13

Author Correction: Pathway and network analysis of more than 2500 whole cancer genomes (Nature Communications, (2020), 11, 1, (729), 10.1038/s41467-020-14367-0)

Journal article

Reyna MA. et al, (2022), Nature Communications, 13

TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions

Journal article

Daver NG. et al, (2022), Cancer Discovery, OF1 - OF14

A Phase 3, Randomized Trial of Magrolimab in Combination With Venetoclax and Azacitidine in Previously Untreated Patients With Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy (ENHANCE-3)

Conference paper

Daver N. et al, (2022), AMERICAN JOURNAL OF HEMATOLOGY, 97, S5 - S5

A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Azacitidine in Previously Untreated Patients With TP53-Mutant Acute Myeloid Leukemia

Conference paper

Daver N. et al, (2022), AMERICAN JOURNAL OF HEMATOLOGY, 97, S5 - S6

AML-262 Pivekimab Sunirine (PVEK, IMGN632) Triplet With Azacitidine and Venetoclax Shows Broad Activity in Adverse Genetic Subsets of Relapsed/Refractory Acute Myeloid Leukemia and Reduced Infusion-Related Reactions

Journal article

Daver N. et al, (2022), Clinical Lymphoma, Myeloma and Leukemia, 22, S231 - S232

AML-348 A Phase Ib/II Study of Ivosidenib With Venetoclax +/- Azacitidine in IDH1-Mutated Hematologic Malignancies

Journal article

Lachowiez C. et al, (2022), Clinical Lymphoma, Myeloma and Leukemia, 22, S240 - S241

AML-399 A Phase 2, Open-Label, Multiarm, Multicenter Study to Evaluate Magrolimab Combined With Antileukemia Therapies for First-Line, Relapsed/Refractory, or Maintenance Treatment of Acute Myeloid Leukemia (AML)

Journal article

Vyas P. et al, (2022), Clinical Lymphoma, Myeloma and Leukemia, 22

AML-432 Overall Survival (OS) by IDH2 Mutant Allele (R140 or R172) in Patients With Late-Stage, Mutant-IDH2 Relapsed/Refractory Acute Myeloid Leukemia (AML) Treated With Enasidenib or Conventional Care Regimens (CCR) in the Randomized, Open-Label, Phase 3 IDHENTIFY Trial

Journal article

DiNardo CD. et al, (2022), Clinical Lymphoma, Myeloma and Leukemia, 22, S249 - S250

AML-464 Tolerability and Efficacy of the First-In-Class Anti-CD47 Antibody Magrolimab Combined With Azacitidine in Frontline Patients With TP53-Mutated Acute Myeloid Leukemia (AML): Phase 1b Results

Journal article

Daver N. et al, (2022), Clinical Lymphoma, Myeloma and Leukemia, 22, S253 - S254

Magrolimab in Combination With Azacitidine for Patients With Untreated Higher-Risk Myelodysplastic Syndromes: 5F9005 Phase 1b Study Results

Conference paper

Sallman DA. et al, (2022), AMERICAN JOURNAL OF HEMATOLOGY, 97, S20 - S21

MDS-445 Magrolimab In Combination With Azacitidine for Patients With Untreated Higher-Risk Myelodysplastic Syndromes (HR MDS): 5F9005 Phase 1b Study Results

Journal article

Sallman D. et al, (2022), Clinical Lymphoma, Myeloma and Leukemia, 22, S314 - S315

MDS-482 Impact Of Magrolimab in Combination With Azacitidine on Red Blood Cells (RBCs) in Patients With Higher-Risk Myelodysplastic Syndromes (HR MDS)

Journal article

Chen J. et al, (2022), Clinical Lymphoma, Myeloma and Leukemia, 22, S317 - S318

A tubulin binding molecule drives differentiation of acute myeloid leukemia cells.

Journal article

Jackson TR. et al, (2022), iScience, 25

Load More